April 7 - Gilead said on Tuesday it will acquire privately held Tubulis GmbH, a Germany-based biotechnology company, in a transaction valued at as much as $5 billion. The purchase is designed to bring Tubulis' experimental cancer therapies into Gilead's development pipeline.
Under the terms of the agreement, Gilead will pay $3.15 billion in cash at closing for all outstanding equity of Tubulis, with the potential for an additional $1.85 billion tied to future milestones. Those contingent payments would bring the total deal value to a maximum of $5 billion.
Gilead's stated objective in the acquisition is to obtain Tubulis' portfolio of experimental agents classified as antibody-drug conjugates, often described as "guided missiles." These agents are designed to deliver chemotherapy payloads directly to cancer cells while limiting exposure to healthy tissue, a mechanism that aims to increase efficacy and reduce systemic toxicity.
The Tubulis agreement is the latest in a series of strategic deals by Gilead as it broadens its focus beyond its established areas of growth. The company has faced pressures from looming patent expiries and a decline in sales of Veklury, its COVID-19 treatment, factors cited by Gilead as drivers of its recent acquisition activity.
Earlier this year, in February, Gilead agreed to acquire partner Arcellx in a transaction worth up to $7.8 billion, a move intended to strengthen its oncology offerings. More recently, last month, the company reached an agreement to acquire privately held Ouro Medicines for a deal valued at more than $2 billion to expand its pipeline of drugs for immune disorders. The Tubulis transaction follows these purchases as part of a broader push to supplement Gilead's drug development pipeline.
For investors and industry observers, the deal structure underscores a common approach in biopharma M&A: a substantial upfront payment combined with milestone-based contingent considerations tied to future development, regulatory, or commercial events. In this case, $3.15 billion is payable immediately at closing, while up to $1.85 billion would be payable if specified targets are met.
Gilead's move to add antibody-drug conjugates complements its recent acquisitions and reflects a targeted effort to expand into promising oncology modalities. At the same time, the company is responding to near-term revenue challenges flagged by reduced Veklury sales and the prospect of patent expirations that could weigh on future growth.
As with any transaction that includes milestone payments, the ultimate price paid will depend on the clinical and commercial progress of Tubulis' programs. The acquisition completes another step in Gilead's recent deal-making spree as it reshapes its pipeline amid shifting revenue dynamics.
Key points
- Gilead will acquire Tubulis for $3.15 billion upfront plus up to $1.85 billion in milestone payments, for a maximum value of $5 billion.
- The acquisition gives Gilead access to Tubulis' experimental antibody-drug conjugates, commonly called "guided missiles," which deliver chemotherapy directly to cancer cells while aiming to spare healthy tissue.
- The deal follows recent acquisitions of Arcellx (up to $7.8 billion) and Ouro Medicines (more than $2 billion) as Gilead seeks to bolster its pipeline amid patent expiries and declining Veklury sales.
Risks and uncertainties
- The milestone portion of the purchase price - up to $1.85 billion - is contingent on future events and not guaranteed.
- Gilead faces pressure from looming patent expiries and reduced sales of its COVID-19 treatment, Veklury, which have been factors in its recent acquisition strategy.